The investor thrill that cutbacks last spring failed to provide for Avant Immunotherapeutics Inc. came in spades with news of the company's merger with Celldex Therapeutics Inc., and the all-stock deal creates a new firm worth about $115 million, (based on Avant's closing price Oct. 19), giving privately held Celldex about 58 percent ownership of the new company. (BioWorld Today)